共 122 条
[1]
Attal M(2017)Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma N Engl J Med 376 1311-20
[2]
Lauwers-Cances V(2020)Newly diagnosed myeloma in 2020 Am Soc Clin Oncol Educ Book 40 1-15
[3]
Hulin C(2012)Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Blood 120 1589-96
[4]
Leleu X(2016)VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial Blood 127 2569-74
[5]
Caillot D(2017)Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 28 iv52-61
[6]
Escoffre M(2014)International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 15 e538-548
[7]
Moreau P(1995)An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy Blood 86 3961-9
[8]
Touzeau C(2009)Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma Bone Marrow Transplant 43 619-25
[9]
Vij R(2009)International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) Leukemia 23 1904-12
[10]
Goldsmith SR(2009)Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma Blood 113 5720-6